

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

APC anti-mouse CD137

RRID:AB_2564296

Type: Antibody

Proper Citation

BioLegend Cat# 106109, RRID:AB_2564296

Antibody Information

URL: http://antibodyregistry.org/AB_2564296

Proper Citation: BioLegend Cat# 106109, RRID:AB_2564296

Target Antigen: CD137

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-mouse CD137

Description: This monoclonal targets CD137

Target Organism: mouse

Clone ID: Clone 17B5

Antibody ID: AB_2564296

Vendor: BioLegend

Catalog Number: 106109

Alternative Catalog Numbers: 106110

Record Creation Time: 20250820T024938+0000

Record Last Update: 20250820T143723+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse CD137.

No alerts have been found for APC anti-mouse CD137.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kondo T, et al. (2025) Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. *Cell*, 188(9), 2372.

Calôba C, et al. (2025) Systemic 4-1BB stimulation augments extrafollicular memory B cell formation and recall responses during Plasmodium infection. *Cell reports*, 44(4), 115528.

Abdullah L, et al. (2025) The endogenous antigen-specific CD8+ T cell repertoire is composed of unbiased and biased clonotypes with differential fate commitments. *Immunity*, 58(3), 601.

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Yakkala C, et al. (2024) Cryoablation Does Not Significantly Contribute to Systemic Effector Immune Responses in a Poorly Immunogenic B16F10 Melanoma Model. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4190.

Andreata F, et al. (2024) Therapeutic potential of co-signaling receptor modulation in hepatitis B. *Cell*, 187(15), 4078.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer cell*, 39(12), 1623.

Chow MT, et al. (2019) Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. *Immunity*, 50(6), 1498.

Huang Z, et al. (2017) The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling Sympathetic Nervous System to Type 2 Immunity. *Cell metabolism*, 26(3), 493.